LuciBal (Baloxavir marboxil Tablet 20mg)
EACH FILM-COATED LUCIBAL TABLET CONTAINS: Baloxavir marboxil……………..20mg
INDICATIONS
Treatment of Influenza
LuciBal is indicated for treatment of acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications.
Post-Exposure Prophylaxis of Influenza
LuciBal is indicated for post-exposure prophylaxis of influenza in persons 5 years of age and older following contact with an individual who has influenza.
Limitations of Use
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use LuciBal.
DOSAGE
LuciBal should be taken as soon as possible after influenza symptom onset or exposure to influenza and may be taken with or without food. However, coadministration of LuciBal with dairy products, calcium- fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc) should be avoided.
- Recommended Dosage
Treatment of Acute Uncomplicated Influenza or Post-Exposure Prophylaxis in Adults, and Pediatric Patients (5 Years of Age and Older)
LuciBal should be taken as a single dose as soon as possible and within 48 hours of influenza symptom onset for treatment of acute uncomplicated influenza or following contact with an individual who has influenza. The recommended dosage of LuciBal in patients 5 years of age or older is a single weight-based dose displayed in Tables 1.
Table 1 Recommended LuciBal Tablet Dosage in Adults and Pediatric Patients 5 Years of Age and Older
| Patient Body Weight (kg) | Recommended Single Oral Dose (Tablets) |
| Less than 20 kg, | 2 mg/kg |
| 20 kg to less than 80 kg | 40 mg |
| At least 80 kg | 80 mg |
STORAGE
Store at 20℃ to 25℃ (68℉ to 77℉), excursions permitted between 15℃ and 30℃ (59℉ and 86℉) [see USP Controlled Room Temperature]. Protect from moisture.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
Address: Thongmang village, Xaythany district, Vientiane Capital, Laos
Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/baloxavir-marboxil-tablets/
Related News
-
RASONQUE™ (Daraxonrasib) Clinical Trials, Distribution & Value in Precision Oncology
Clinical Trials of RASONQUE™ (Daraxonrasib) The clinical development of RASONQUE™ (Daraxonrasib) has…
2026-10-05
-
RASONQUE™(Daraxonrasib): Dosage Instructions, Side Effects, FAQ & Myths
How to Take RASONQUE™ (Daraxonrasib) Safely and Effectively Take it exactly as…
2026-10-03
-
Turning Off the Signal That Fuels Cancer: RASONQUE™ (Daraxonrasib) Overview
Turning Off the Signal That Fuels Cancer: RASONQUE™ (Daraxonrasib) Overview When Every…
2026-10-01
-
Understanding ATTR-CM: A Patient-Friendly Guide to Transthyretin Amyloidosis Cardiomyopathy
1. Experience: What Living with ATTR-CM Can Feel Like Symptoms of ATTR-CM…
2026-09-04
-
LuciOdevi FAQs, Myths, Clinical‑Trial Data & Medication Distribution Guide | Lucius Pharmaceuticals
Frequently Asked Questions About LuciOdevi Q1. What is LuciOdevi?A: LuciOdevi is an…
2026-08-14
-
Unveiling New Possibilities in the Treatment of Cholestatic Liver Disorders: LuciOdevi 400mcg Developed by Lucius Pharmaceuticals
Introduction Cholestatic liver disorders cover a broad, hard‑to‑treat group of hepatobiliary illnesses…
2026-08-11



